Login to Your Account



Bluebird Bio, Celgene Hatch Gene Therapy Collaboration

By Marie Powers
Staff Writer

Thursday, March 21, 2013

Privately held gene therapy company bluebird bio soared to new heights in a discovery, development and commercialization deal with big biotech Celgene Corp. to use its technology to genetically modify a patient's own T cells to target and destroy cancer cells. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription